Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) induces long-term responses in patients with relapsed or refractory follicular lymphoma (FL).

被引：3
|
作者：
Schilder, RJ
Witzig, TE
Flinn, I
Gordon, LI
Emmanouilides, C
Wang, H
Vo, K
Molina, A
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[2] Mayo Clin, Dept Hematol Oncol, Rochester, MN USA
[3] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA
[4] Northwestern Univ, Div Hematol Oncol, Chicago, IL 60611 USA
[5] Univ Calif Los Angeles, Div Hematol Oncol, Los Angeles, CA 90024 USA
[6] Biogen Idec Inc, Global Med Affairs, San Diego, CA USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.2629.2629
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2629
引用
收藏
页码：719A / 719A
页数：1
相关论文
共 50 条
  • [31] Feasibility of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) radioimmunotherapy for non-Hodgkin's lymphoma in a patient with chronic renal failure.
    Spies, SM
    Gordon, LI
    Zimmer, AM
    Cutrera, P
    BLOOD, 2004, 104 (11) : 244B - 244B
  • [32] Radioimmunotherapy with 90Y-ibritumomab tiuxetan for a hemodialysis patient with relapsed follicular lymphoma
    Fukuno, Kenji
    Tsurumi, Hisashi
    Yamada, Toshiki
    Iida, Takayoshi
    Takahashi, Takeshi
    Moriwaki, Hisataka
    LEUKEMIA & LYMPHOMA, 2013, 54 (12) : 2731 - 2733
  • [33] Safety and Efficacy of 90Y Ibritumomab Tiuxetan (Zevalin®)) for Untreated FollicularNon-Hodgkin's Lymphoma (FL) Patients, An Italian Cooperative Study
    Pica, G.
    Nati, S.
    Vitolo, Umberto
    Galimberti, Sara
    Zinzani, Pier Luigi
    Cascavilla, Nicola
    Petrini, Mario
    Carella, A. M.
    BLOOD, 2011, 118 (21) : 49 - 49
  • [34] Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma
    Witzig, TE
    SEMINARS IN ONCOLOGY, 2003, 30 (06) : 11 - 16
  • [35] Consolidation with90Yttrium-ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma
    Miura, Katsuhiro
    Tsujimura, Hideki
    Masaki, Yasufumi
    Iino, Masaki
    Takizawa, Jun
    Maeda, Yoshinobu
    Yamamoto, Kazuhiko
    Tamura, Shinobu
    Yoshida, Akiyo
    Yagi, Hideo
    Yoshida, Isao
    Kitazume, Koichi
    Masunari, Taro
    Choi, Ilseung
    Kakinoki, Yasutaka
    Suzuki, Ritsuro
    Yoshino, Tadashi
    Nakamura, Shigeo
    Hatta, Yoshihiro
    Yoshida, Takashi
    Kanno, Masatoshi
    HEMATOLOGICAL ONCOLOGY, 2021, 39 (01) : 51 - 59
  • [36] Radioimmunotherapy with 90Y Ibritumomab Tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
    Palumbo, B.
    Sabalich, I.
    Falcinelli, F.
    Capponi, M.
    Martelli, M.
    Palumbo, R.
    Sinzinger, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S419 - S419
  • [37] Long-term responses in patients with recurring or refractory B-Ccll non-hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan
    Witzig, Thomas E.
    Molina, Arturo
    Gordon, Leo I.
    Emmanouilides, Christos
    Schilder, Russell J.
    Flinn, Ian W.
    Darif, Mohamed
    Macklis, Roger
    Vo, Katie
    Wiseman, Gregory A.
    CANCER, 2007, 109 (09) : 1804 - 1810
  • [38] Efficacy of 90Y-ibritumomab tiuxetan (Zevalin) in refractory or relapsed MALT gastric non Hodgkin's lymphoma.
    Vanazzi, Anna
    Ferrucci, Pier F.
    Grana, Chiara
    Pruneri, Giancarlo
    Crosta, Cristiano
    Pinto, Antonello
    Chinol, Marco
    Paganelli, Giovanni
    Martinelli, Giovanni
    BLOOD, 2006, 108 (11) : 784A - 784A
  • [39] Yttrium 90 ibritumomab tiuxetan (Zevalin®) radioimmunotherapy (RIT) induces durable remissions in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL):: Analysis of long-term responders.
    Witzig, TE
    Molina, A
    Gordon, LI
    Emmanouilides, C
    Schilder, RJ
    Flinn, I
    Czuczman, M
    Wang, H
    Theuer, C
    Wiseman, G
    BLOOD, 2003, 102 (11) : 407A - 407A
  • [40] Cellular localization pattern of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) in a patient with low-grade non-Hodgkin's lymphoma (NHL).
    Jacobs, SA
    Harrison, AM
    Swerdlow, SH
    Foon, KA
    Avril, N
    Vidnovic, N
    McCarty, KS
    Saville, W
    BLOOD, 2004, 104 (11) : 226B - 226B
12345